A First-in-human Clinical Evaluation of SN132D in Patients With Breast Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This phase I, first-in-human (FIH) study is open-label, non-randomised and
non-placebo-controlled. The study is designed to evaluate the safety, tolerability and
pharmacokinetics (PK) of a single intravenous dose of SN132D in up to 20 patients with breast
cancer. Magnetic resonance imaging (MRI) will be performed pre- and post-infusion of SN132D.